Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Alkermes enters sleep medicine market through Avadel acquisition

Alkermes enters sleep medicine market through Avadel acquisition

Money Moves

Irish drugmaker gains LUMRYZ narcolepsy treatment and pipeline access after winning bidding war with Lundbeck

February 12th, 2026: Alkermes Completes Avadel Acquisition

Overview

Alkermes, a neuroscience-focused pharmaceutical company, completed its $2.37 billion acquisition of Avadel Pharmaceuticals on February 12, 2026, gaining immediate entry into the sleep medicine market. The deal adds LUMRYZ, the only once-nightly narcolepsy treatment, to Alkermes' portfolio alongside an emerging pipeline of orexin-based therapies.

The acquisition came after Alkermes outmaneuvered Danish pharma company Lundbeck in a month-long bidding war. Avadel shareholders received $21 per share plus contingent value rights tied to future regulatory approvals, ending Avadel's six-year run as an independent company. The deal positions Alkermes to compete directly with Jazz Pharmaceuticals, whose Xyrem and Xywav products dominate the $4 billion narcolepsy market.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

$2.37B
Total Deal Value
Includes $21 per share cash plus contingent value rights worth up to $1.50 per share
$169M
LUMRYZ 2024 Revenue
Full-year net product revenue, up from $28 million in 2023, representing 500% growth
2,500
LUMRYZ Patients
Patients on LUMRYZ as of December 2024, up 275% from 900 patients one year earlier
~200,000
US Narcolepsy Patients
Estimated Americans with narcolepsy, though roughly half remain undiagnosed

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

May 2023 February 2026

8 events Latest: February 12th, 2026 · 5 months ago
Tap a bar to jump to that date
  1. Alkermes Completes Avadel Acquisition

    Latest M&A

    Irish High Court approves the scheme of arrangement. Alkermes completes the acquisition using $775 million in cash and $1.525 billion in term loans due 2031. Avadel shares delisted from Nasdaq.

  2. Alixorexton Receives Breakthrough Therapy Designation

    Regulatory

    FDA grants Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, strengthening the company's sleep medicine pipeline ahead of the Avadel deal closing.

  3. Lundbeck Withdraws from Bidding

    M&A

    Lundbeck announces it will not increase its offer, ending the bidding war and clearing the path for Alkermes to complete the acquisition.

  4. Alkermes Raises Offer to $2.37 Billion

    M&A

    Alkermes increases its bid to $21 per share plus a $1.50 contingent value right tied to FDA approval of LUMRYZ for idiopathic hypersomnia by 2028. Avadel board determines this offer superior to Lundbeck's proposal.

  5. Lundbeck Submits Unsolicited Bid

    M&A

    Danish pharmaceutical company Lundbeck disrupts the deal with an unsolicited $2.4 billion offer, proposing $21 per share plus a $2 contingent value right.

  6. Alkermes Announces Agreement to Acquire Avadel

    M&A

    Alkermes announces definitive agreement to acquire Avadel for up to $2.1 billion, offering $18.50 per share plus a $1.50 contingent value right.

  7. LUMRYZ Approved for Pediatric Patients

    Regulatory

    FDA expands LUMRYZ approval to include children aged 7 and older with narcolepsy, granting orphan drug exclusivity through 2031.

  8. FDA Approves LUMRYZ for Adults

    Regulatory

    Avadel receives FDA approval for LUMRYZ as the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

July 2005

Jazz Pharmaceuticals Acquires Orphan Medical (2005)

Jazz Pharmaceuticals acquired Orphan Medical for approximately $123 million, gaining Xyrem (sodium oxybate), a treatment for narcolepsy cataplexy. At the time, Xyrem was a niche product treating a rare condition with limited commercial potential.

Then

Jazz gained an FDA-approved narcolepsy treatment and established its presence in sleep medicine.

Now

Xyrem became a blockbuster, reaching $1.7 billion in peak annual sales by 2020. The deal transformed Jazz from a struggling startup into a major specialty pharmaceutical company.

Why this matters now

Alkermes is following a similar playbook—acquiring a commercial-stage narcolepsy product (LUMRYZ) and combining it with pipeline assets. The Jazz precedent suggests significant long-term value creation is possible in this market.

May 2020

AbbVie-Allergan Merger Creates Aesthetics and Neuroscience Giant (2020)

AbbVie completed its $63 billion acquisition of Allergan, combining AbbVie's immunology portfolio with Allergan's neuroscience, aesthetics, and eye care businesses. The deal faced regulatory scrutiny requiring divestitures and took over a year to complete.

Then

AbbVie gained Botox, Vraylar, and other neuroscience products, diversifying beyond its flagship Humira.

Now

The combined company became a dominant force in neuroscience and aesthetics, validating large-scale consolidation in specialty pharmaceuticals.

Why this matters now

Both deals involve a larger company acquiring a smaller one to enter or expand in neuroscience. The AbbVie-Allergan deal shows how strategic acquisitions can create significant value when combined with existing capabilities and distribution.

March 2022

Axsome Therapeutics Acquires Sunosi from Jazz Pharmaceuticals (2022)

Axsome Therapeutics acquired Sunosi (solriamfetol), a wakefulness-promoting agent for narcolepsy and sleep apnea, from Jazz Pharmaceuticals for up to $565 million. Jazz divested the product to focus on its oxybate franchise.

Then

Axsome gained an approved sleep medicine product complementing its CNS pipeline.

Now

The deal demonstrated that Jazz was willing to shed non-core sleep assets while defending its oxybate market position.

Why this matters now

The Sunosi divestiture showed Jazz's strategic focus on oxybate products. Alkermes now enters this market with LUMRYZ, a direct oxybate competitor, testing whether Jazz can maintain dominance against a well-capitalized challenger.

Sources

(10)